Financials Arrowhead Pharmaceuticals, Inc.

Equities

ARWR

US04280A1007

Biotechnology & Medical Research

Real-time Estimate Cboe BZX Other stock markets 18:18:24 05/12/2025 GMT			5-day change	1st Jan Change
61.38 ^USD	-5.06%		+17.20%	+228.54%

12-02	Arrowhead Pharmaceuticals Gets FDA Breakthrough Tag for Triglyceride Drug	MT
12-02	Arrowhead Pharmaceuticals receives FDA breakthrough therapy designation for plozasiran	RE

Projected Income Statement: Arrowhead Pharmaceuticals, Inc.

Fiscal Period: September	2021	2022	2023	2024	2025	2026	2027	2028
Net sales ¹	138.3	243.2	240.7	3.551	829.4	399.9	278.6	516.5
Change	-	75.89%	-1.03%	-98.52%	23,258.15%	-51.79%	-30.32%	85.38%
EBITDA ¹	-140.8	-168.1	-192.5	-582.5	-	-258	-592.8	-576.7
Change	-	-19.41%	-14.53%	-202.58%	-	-	-129.8%	2.71%
EBIT ¹	-149	-178.5	-205	-601.1	98.35	-411	-590.4	-433.9
Change	-	-19.77%	-14.84%	-193.21%	116.36%	-517.94%	-43.63%	26.51%
Interest Paid ¹	-	-	-1.489	-11.38	-	-45.85	-46.72	-39.27
Earnings before Tax (EBT) ¹	-140.8	-172.7	-206.5	-612.5	51.53	-482.4	-598.6	-389
Change	-	-22.62%	-19.56%	-196.6%	108.41%	-1,036.19%	-24.08%	35.01%
Net income ¹	-140.8	-176.1	-205.3	-599.5	-1.631	-442.5	-570.3	-383.6
Change	-	-25%	-16.59%	-192.04%	99.73%	-27,029.87%	-28.89%	32.75%
Announcement Date	22/11/21	28/11/22	29/11/23	26/11/24	25/11/25	-	-	-

¹USD in Million

Estimates

Fiscal Period: September	2021 Q1	2021 Q2	2021 Q3	2021 Q4	2022 Q1	2022 Q2	2022 Q3	2022 Q4	2023 Q1	2023 Q2	2023 Q3	2023 Q4	2024 Q1	2024 Q2	2024 Q3	2024 Q4	2025 Q1	2025 Q2	2025 Q3	2025 Q4	2026 Q1	2026 Q2	2026 Q3	2026 Q4	2027 Q1	2027 Q2	2027 Q3	2027 Q4
Net sales ¹	21.3	32.81	45.89	38.28	27.44	151.8	32.41	31.58	62.55	146.3	15.82	16.1	3.551	-	-	-	2.5	542.7	27.77	256.5	244.9	58.91	41.61	40.77	56.44	39.75	42.3	132.7
Change	-	54.02%	39.86%	-16.58%	-28.33%	453.25%	-78.65%	-2.58%	98.09%	133.86%	-89.18%	1.72%	-77.94%	-	-	-	-	21,608.36%	-94.88%	823.66%	-4.53%	-75.94%	-29.36%	-2.01%	38.42%	-29.57%	6.41%	213.84%
EBITDA ¹	-22.21	-26.31	-29.87	-62.38	-60.75	44.15	-70.32	-81.17	-39.44	50.83	-99.43	-104.5	-132.3	-121.7	-171.4	-157.2	-	-	-159.3	-	222.6	-144.4	-183.4	-193.8	-	-	-	-
Change	-	-18.5%	-13.52%	-108.83%	2.61%	172.67%	-259.27%	-15.44%	51.4%	228.87%	-295.59%	-5.07%	-26.62%	8.03%	-40.84%	8.28%	-	-	-	-	-	-164.88%	-26.98%	-5.68%	-	-	-	-
EBIT ¹	-24.05	-28.23	-31.87	-64.88	-63.32	41.55	-72.91	-83.83	-42.13	48.16	-102.7	-108.3	-136.5	-126.2	-176.1	-162.2	-161.4	381.2	-165.6	44.11	41.37	-144.7	-177	-183.3	-165.6	-167.8	-164.2	-166.7
Change	-	-17.37%	-12.88%	-103.6%	2.41%	165.62%	-275.46%	-14.98%	49.74%	214.31%	-313.23%	-5.48%	-26.05%	7.58%	-39.58%	7.91%	0.49%	336.17%	-143.43%	126.64%	-6.21%	-449.71%	-22.36%	-3.53%	9.66%	-1.33%	2.15%	-1.53%
Charge d'intérêts ¹	-	-	-	-	-	-	-	-	-	-	-0.986	-0.66	-2.144	-0.805	1.404	-9.835	-13.7	-11.59	-13.54	-	-9.933	-10.8	-11.67	-11.03	-14.7	-15.8	-16.9	-18
Earnings before Tax (EBT) ¹	-20.73	-26.82	-29.92	-63.37	-62.87	44.37	-72.05	-82.16	-41.79	47.68	-103.4	-109	-138.7	-127	-174	-172.8	-175.1	369.6	-179.1	36.12	12.74	-149.3	-181.2	-186.8	-180.3	-183.6	-181.1	-184.7
Change	-	-29.36%	-11.58%	-111.78%	0.79%	170.57%	-262.39%	-14.03%	49.13%	214.07%	-316.84%	-5.42%	-27.25%	8.43%	-36.99%	0.68%	-1.34%	311.07%	-148.45%	120.17%	-64.72%	-1,271.67%	-21.34%	-3.08%	3.47%	-1.83%	1.37%	-2%
Net income ¹	-20.73	-26.82	-29.92	-63.37	-62.87	44.37	-72.05	-85.51	-41.81	47.68	-102.9	-109.7	-132.9	-125.3	-170.8	-170.5	-173.1	370.4	-175.2	-23.75	12.75	-143.5	-171.7	-176.2	-180.8	-184.6	-182.6	-186.7
Change	-	-29.36%	-11.58%	-111.78%	0.79%	170.57%	-262.39%	-18.69%	51.1%	214.03%	-315.93%	-6.54%	-21.14%	5.69%	-36.31%	0.15%	-1.49%	314.02%	-147.31%	86.45%	153.68%	-1,225.33%	-19.68%	-2.61%	-2.6%	-2.1%	1.09%	-2.25%
Announcement Date	04/02/21	04/05/21	05/08/21	22/11/21	02/02/22	10/05/22	04/08/22	28/11/22	06/02/23	02/05/23	07/08/23	29/11/23	06/02/24	09/05/24	08/08/24	26/11/24	10/02/25	12/05/25	07/08/25	25/11/25	-	-	-	-	-	-	-	-

¹USD in Million

Estimates

Forecast Balance Sheet: Arrowhead Pharmaceuticals, Inc.

Fiscal Period: September	2021	2022	2023	2024	2025	2026	2027	2028
Net Debt ¹	-368	-108	-111	-103	-	-940	-1,018	-667
Change	-	70.65%	-2.78%	7.21%	-	-	-8.3%	34.48%
Announcement Date	22/11/21	28/11/22	29/11/23	26/11/24	25/11/25	-	-	-

¹USD in Million

Estimates

Cash Flow Forecast: Arrowhead Pharmaceuticals, Inc.

Fiscal Period: September	2021	2022	2023	2024	2026	2027	2028
CAPEX ¹	23.57	52.78	176.7	141.5	15.65	14.13	13.2
Change	-	123.94%	234.88%	-19.96%	-	-9.69%	-6.6%
Free Cash Flow (FCF) ¹	147.7	-188.9	-330.6	-604.3	-230	-400	-402
Change	-	-227.94%	-75.02%	-82.78%	-	-73.89%	-0.53%
Announcement Date	22/11/21	28/11/22	29/11/23	26/11/24	-	-	-

¹USD in Million

Estimates

Forecast Financial Ratios: Arrowhead Pharmaceuticals, Inc.

Fiscal Period: September	2021	2022	2023	2024	2025	2026	2027	2028
Profitability
EBITDA Margin (%)	-101.79%	-69.11%	-79.97%	-16,403.41%	-	-64.52%	-212.78%	-111.67%
EBIT Margin (%)	-107.77%	-73.39%	-85.16%	-16,927.06%	11.86%	-102.79%	-211.89%	-84%
EBT Margin (%)	-101.85%	-71.01%	-85.78%	-17,247.54%	6.21%	-120.65%	-214.85%	-75.32%
Net margin (%)	-101.85%	-72.39%	-85.27%	-16,882.37%	-0.2%	-110.66%	-204.71%	-74.27%
FCF margin (%)	106.78%	-77.67%	-137.34%	-17,018.3%	-	-57.52%	-143.55%	-77.84%
FCF / Net Income (%)	-104.83%	107.3%	161.07%	100.81%	-	51.98%	70.12%	104.82%
Profitability
ROA	-	-	-	-	-	-	-	-
ROE	-14.56%	-43.62%	-61.29%	-262.48%	-	-25.79%	-75.35%	-84.47%
Financial Health
Leverage (Debt/EBITDA)	-	-	-	-	-	-	-	-
Debt / Free cash flow	-	-	-	-	-	-	-	-
Capital Intensity
CAPEX / Current Assets (%)	17.04%	21.7%	73.42%	3,983.92%	-	3.91%	5.07%	2.56%
CAPEX / EBITDA (%)	-16.74%	-31.4%	-91.81%	-24.29%	-	-6.07%	-2.38%	-2.29%
CAPEX / FCF (%)	15.96%	-27.94%	-53.46%	-23.41%	-	-6.8%	-3.53%	-3.28%
Items per share
Cash flow per share ¹	-	-	-	-1.146	-	-0.9347	-2.772	-
Change	-	-	-	-	-	-	-196.51%	-
Dividend per Share ¹	-	-	-	-	-	-	-	-
Change	-	-	-	-	-	-	-	-
Book Value Per Share ¹	3.919	3.761	2.528	1.491	-	3.98	3.94	1.61
Change	-	-4.02%	-32.77%	-41.03%	-	-	-1.01%	-59.14%
EPS ¹	-1.36	-1.67	-1.92	-5	-0.01	-3.303	-4.079	-2.644
Change	-	-22.79%	-14.97%	-160.42%	99.8%	-32,933.3%	-23.48%	35.19%
Nbr of stocks (in thousands)	104,259	105,849	107,193	124,315	138,258	135,810	135,810	135,810
Announcement Date	22/11/21	28/11/22	29/11/23	26/11/24	25/11/25	-	-	-